All In Biotech

Drug Trial Radar · NCT02504489

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 559 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

559

Actual

Start

Dec 2015

Primary completion

Jul 21, 2021

Study completion Oct 30, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. Secondary purposes of the study are: * To compare overall response rate (ORR) of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare progression free survival (PFS) of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare incidence of Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 109/L) on Day 8 (+/- 1 day) of Cycle 1 of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare 24-month and 36-month OS rate of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • Docetaxel + Plinabulin (DP)Drug

    Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2

  • Docetaxel (D)Drug

    Docetaxel 75 mg/m2 IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: The time (Days) from the date of randomization to the date of death, up to 48 months

Locations

57 sites in 3 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Memorial Health Care System

    Colorado Springs, Colorado

  • Cancer Center of Central Connecticut

    Plainville, Connecticut

  • Peachtree Hematoloy-Oncology Consultants, PC

    Atlanta, Georgia

  • Orchard Healthcare Research Inc.

    Skokie, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • Kansas University Medical Center

    Westwood, Kansas

  • University of Louisville-Brown Cancer Center

    Louisville, Kentucky

  • Henry Ford Hospital

    Detroit, Michigan

  • Michigan Center of Medical Research

    Farmington Hills, Michigan

  • Hattiesburg Clinic Hematology/Oncology

    Hattiesburg, Mississippi

  • Central Care Cancer Center

    Bolivar, Missouri

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Toledo Cancer Center

    Toledo, Ohio

  • Allegheny Health Network

    Pittsburgh, Pennsylvania

  • Cookeville Regional Medical Center Cancer Center

    Cookeville, Tennessee

  • Blacktown Cancer Centre

    Blacktown, New South Wales, Australia

  • Border Medical Oncology Research Unit

    East Albury, New South Wales, Australia

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • Adult Mater Hospital

    South Brisbane, Queensland, Australia

  • Peninsula and South East Oncology

    Melbourne, Victoria, Australia

  • Epworth Hospital

    Richmond, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Perth Oncology/Mount Hospital

    Perth, Western Australia, Australia

  • St John of God Hospital, Subiaco

    Subiaco, Western Australia, Australia

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • The PLA General Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China

  • Guizhou Provincial Hospital

    Guiyang, Guizhou, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Affiliated Cancer Hospital of Harbin Medical Unive

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The Second Xiangya Hospital of Central South Unive

    Changsha, Hunan, China

  • Jiangyin People's Hospital

    Jiangyin, Jiangsu, China

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.